

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,900

Open access books available

186,000

International authors and editors

200M

Downloads

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.

For more information visit www.intechopen.com



Mitochondrial Abnormalities in Down Syndrome: Pathogenesis, Effects and Therapeutic Approaches

Antonella Izzo, Nunzia Mollo, Rita Cicatiello,
Rita Genesio, Simona Paladino, Anna Conti and
Lucio Nitsch

Additional information is available at the end of the chapter

<http://dx.doi.org/10.5772/intechopen.71059>

Abstract

Down syndrome (DS) consists of a complex phenotype with constant features, such as mental retardation and hypotonia, and variable features, including heart defects and susceptibility to Alzheimer's disease, type 2 diabetes, obesity and immune disorders. Overexpression of genes mapping to chromosome 21 (Hsa21) is directly or indirectly responsible for pathogenesis of DS phenotypic features, as overexpressed Hsa21 genes dysregulate several other genes mapping to different chromosomes. Many of these genes are involved in mitochondrial function. Recent studies highlight a link between mitochondrial dysfunction, consistently observed in DS subjects, and DS phenotype. In this review, we first provide a basic overview of mitochondrial alterations in DS in terms of mitochondrial bioenergetics, biogenesis and morphology. We then discuss how mitochondrial malfunction may contribute to the pathogenesis of clinical manifestations and how specific Hsa21 genes may cause the disruption of mitochondrial phenotype. Finally, we focus on drugs, which affect mitochondrial function and network to propose possible therapeutic approaches aimed at improving and/or preventing various aspects of the DS phenotype. Our working hypothesis is that correcting the mitochondrial defect might improve the neurological phenotype and prevent DS-associated pathologies, thus providing a better quality of life for DS individuals and their families.

Keywords: Down syndrome, trisomy 21, mitochondrial dysfunction, mitochondrial dynamics, Down syndrome/therapy

1. Introduction

Down syndrome (DS) (OMIM 190685), caused by the trisomy of chromosome 21 (TS21), is the most common autosomal aneuploidy compatible with postnatal survival with a prevalence of

1 in 700 newborns. Its phenotype is highly complex showing constant features, such as mental retardation, dysmorphic traits and hypotonia, and variable features, including heart defects, susceptibility to Alzheimer's disease (AD), type 2 diabetes, obesity and immune disorders. DS is also a risk factor for a number of diseases, such as thyroid dysfunction, leukemia and various other congenital malformations. The mechanisms causing the DS phenotype are still largely unknown and little progress has been registered so far in the therapeutic approach to ameliorate the life of DS subjects.

Overexpression of genes mapping to chromosome 21 (Hsa21) is clearly responsible for pathogenesis of DS phenotypic features either in a direct or indirect manner, as overexpressed Hsa21 genes affect the regulation of several other genes mapping to different chromosomes. Many of these genes are involved in oxidative phosphorylation (OXPHOS) and more generally in the mitochondrial function [1].

As fully described in the following paragraphs, the mitochondrial dysfunction together with the disruption of the mitochondrial network might concur to determine DS phenotypic traits. This suggests that correcting the mitochondrial defect might affect the severity of DS phenotype.

This review provides first a basic overview of mitochondrial alterations in terms of mitochondrial bioenergetics, biogenesis and morphology in DS. The latest theories are reported about: (i) how mitochondrial malfunction may contribute to the pathogenesis of clinical manifestations of DS and (ii) how specific Hsa21 genes may be involved in determining the pathogenesis of mitochondrial dysfunction in DS. Finally, we focus on drugs that target genes and/or pathways involved in mitochondrial function and mitochondrial network to examine potential therapeutic approaches.

2. Mitochondrial abnormalities in DS

Increasing evidences, widely documented in scientific literature, highlight that there is a link between mitochondrial damages and the complex DS phenotype. The downregulation of nuclear-encoded mitochondrial genes (NEMGs) is a hallmark of TS21 in human fetal hearts [1] and brains [2]. Transcriptome analysis of fetal heart tissues showed that more than 400 genes located on chromosomes other than 21 were differentially expressed, either upregulated or downregulated, in trisomic versus non-trisomic hearts [1]. Functional class scoring of these genes revealed a global downregulation of NEMGs. Together with the downregulation of genes involved in mitochondrial pathways, we demonstrated, in trisomic fetal fibroblasts of the same subjects, that mitochondria exhibited morphological abnormalities like increased size, irregular shape and evident breaks, mainly of inner membranes. Mitochondria with concentric and longitudinal cristae were significantly more abundant. Stereological analysis demonstrated that mean mitochondrial volume was significantly lower in DS cells [3, 4]. All indices of mitochondrial respiratory functions were decreased and a significant alteration in the redox homeostasis was observed, highlighted by an increased production of reactive oxygen species (ROS) and a

higher steady level of intra-mitochondrial Ca^{2+} [3]. DS fibroblasts also showed a deficit of whole energy status as demonstrated by a decrease of basal ATP content and of mitochondrial membrane potential (**Figure 1**) [4].

Representative confocal microscopy live cell imaging of TMRM fluorescence in euploid and trisomic fibroblasts. A significant decrease in fluorescence intensity is observed in trisomic samples when compared with euploid ones.

These results were in agreement with different studies that demonstrated a less efficient mitochondrial energy production apparatus in fibroblasts from DS subjects due to the impairment of mitochondrial respiratory chain complex I, ATP synthase, ADP/ATP translocator and adenylate kinase activities [5, 6].

The protein expression of mitochondrial electron transport enzyme subunits has been found decreased in the brain of people affected by DS [7]. Decreased mitochondrial redox activity and membrane potential have also been observed both in DS astrocytes [8, 9] and in the brain of the Ts1Cje mouse model [10]. In neural progenitor cells (NPCs) isolated from the hippocampus of Ts65Dn mice, another widely used model of DS, a severe impairment of mitochondrial bioenergetics and biogenesis and reduced NPCs proliferation were demonstrated [11]. Furthermore, microarray analysis revealed that numerous pathways were altered in Ts65Dn muscle, including pathways involved in ATP biosynthesis [12].

Together with mitochondrial function alterations, a significant disruption of mitochondrial dynamics has been observed in trisomic cells. An increased fragmentation of the mitochondrial network was demonstrated in primary cultures of TS21 astrocytes and neurons [13] and in trisomic fetal fibroblasts [4] (**Figure 2**). In agreement with the impairment of mitochondrial network towards the fragmentation, the expression of *MFN2* and *OPA1*, two fusion-inducing genes, was decreased in the same cells.




Figure 1. A significant decrease of fluorescence intensity demonstrates that membrane potential is reduced in DS fibroblasts.




Figure 2. Mitochondrial network is fragmented in DS fibroblasts.

Representative images showing that the mitochondrial network is less fragmented in euploid fibroblasts than in trisomic ones. Magnifications of intracellular selected details show that the number of mitochondria is significantly higher in trisomic cells compared with non-trisomic cells.

A link between mitophagy and mitochondrial dynamics has been recently demonstrated [14, 15], as mitochondrial fusion and fission play a significant role in disease-related processes, such as mitophagy and apoptosis. Dysfunctional and damaged mitochondria are removed from the mitochondrial network via mitophagy processes. The segregation of impaired mitochondria due either to fission or to inhibition of fusion mechanism is hypothesized to be a requirement for this mitophagic degradation [16]. Mitophagy impairments are involved in the development of several neurodegenerative diseases [17].

The knowledge of molecular bases of mitochondrial dysfunction is allowing to set-up most appropriate therapeutic solutions to counteract it, as more fully described in the following paragraphs.

3. Pathogenesis of mitochondrial dysfunction in DS

3.1. PGC-1 α is a key modulator of mitochondrial biogenesis and respiratory function

A common denominator of most of the events that affect mitochondrial function is the transcriptional coactivator *PGC-1 α /PPARGC-1 α* (peroxisome proliferator-activated receptor gamma coactivator 1alpha), a master regulator of mitochondrial activity [4–6]. *PGC-1 α* , through the interaction with transcriptional partners, such as *NRF1*, *ERRa*, *PPARs* and *YY1*, promotes mitochondrial biogenesis and regulates mitochondrial respiratory capacity [18, 19]. Also these *PGC-1 α* transcriptional partners, as well as many NEMGs, have been found downregulated in DS fetal heart tissue [1] and fibroblasts [3]. *PGC-1 α* knockout mice manifest a reduction of mitochondrial number and of respiratory capacity in skeletal muscle [18].

PGC-1 α transcription and activity are positively regulated by Ca²⁺ signaling and negatively regulated by the Hsa21-coded corepressor *NRIP1* (nuclear receptor interacting protein 1) [19]. Indeed, *PGC-1 α* has been found hypoexpressed at the transcriptional and protein levels in TS21 fetal fibroblasts, directly correlated with the amount of mtDNA, while *NRIP1* was upregulated [3]. *PGC-1 α* activity was also found decreased in the hippocampus of DS patients, as well as in Alzheimer's, Huntington's (HD) and Parkinson's (PD) disease patients [20].

3.2. Role of Hsa21 genes in mitochondrial dysfunction

Little is known about the mechanisms by which trisomy 21 causes the abnormal features typical of the DS phenotype, apart the knowledge that the dosage imbalance of genes on Hsa21 and the resulting dysregulation of genes mapping to different chromosomes share the responsibility for molecular dysfunctions in DS.

Hsa21 gene expression was found globally upregulated 1.5-fold in trisomic samples [1, 2], in full agreement with a gene-dosage effect. A comprehensive meta-analysis from 45 DS gene expression studies [21] identified 77 Hsa21 genes mostly upregulated across all the studies, which are likely involved in the DS phenotype. Six of the genes included in this list, namely *NRIP1*, *SUMO3*, *DYRK1A*, *DSCR1/RCAN1*, *SOD1* and *APP*, are directly or indirectly involved in mitochondrial function. Other Hsa21 genes not included in the Vilardell's list, such as *ETS-2*, *ITSN1*, *PKNOX1/PREP1*, *BACH1* and *S100B*, were found to be involved in apoptotic events and/or to contribute to the regulation of oxidative stress when overexpressed [22]. The dysregulation of one or more of these genes, listed in Table 1, might account for mitochondrial alterations observed in DS, as discussed below.

3.2.1. *NRIP1*

We recently demonstrated that *NRIP1* overexpression is responsible for decreased respiratory efficiency and altered morphology of mitochondria in DS [23]. *NRIP1* is a corepressor that interacts with nuclear receptors and regulates the expression of genes that control metabolic processes such as energy homeostasis [24–27]. Its activity on mitochondrial pathways is

Genes and transcripts	Effects on mitochondrial phenotype
<i>NRIP1/RIP140</i> —nuclear receptor interacting protein 1	Decreases respiratory efficiency and alters morphology of mitochondria
<i>APP</i> —amyloid beta precursor protein	Induces mitochondrial oxidative stress and mitochondrial dysfunction
<i>SUMO3</i> —small ubiquitin-like modifier 3	Modulates <i>NRIP1</i> repressive activity and attenuates the transcriptional activity of <i>PGC-1α</i>
<i>DYRK1A</i> —dual-specificity tyrosine phosphorylation-regulated kinase 1A	Controls <i>PGC-1α</i> via the calcineurin/NFAT pathway
<i>DSCR1/RCAN1</i> —Down Syndrome critical region gene 1	Controls <i>PGC-1α</i> via the calcineurin/NFAT pathway and is associated with calcium overloading
<i>SOD1</i> —superoxide dismutase 1	Is associated with oxidative stress
<i>ETS-2</i> —V-ETS avian erythroblastosis virus E26 oncogene homolog 2	Promotes the activation of a mitochondrial death pathway
<i>ITSN1</i> —Intersectin 1	Regulates the mitochondrial apoptotic pathway
<i>PREP1</i> —PBX-regulating protein 1	Inhibits the OXPHOS negatively regulating <i>PGC-1α</i> and mitochondrial fusion genes <i>OPA1</i> and <i>MFN2</i>
<i>BACH1</i> —BTB domain and CNC homolog 1	Contributes to the early increase of oxidative stress in DS through the inhibition of the <i>HO-1/BVR-A</i> axis
<i>S100B</i> —S100 calcium-binding protein, beta	Overexpression induces ROS formation, activation of stress response kinases and increased programmed cell death
hsa-mir-155	Affects mitochondrial biogenesis by targeting <i>TFAM</i>
hsa-let-7c	May affect mitochondrial function by targeting <i>ANT1</i>

Table 1. Hsa21 genes and transcripts involved in mitochondrial function.

mainly exerted through the repressive control of *PGC-1α* [19]; the two proteins have mutually antagonizing roles in NEMG regulation. In neonatal rat cardiomyocytes, it was demonstrated that overexpressed *NRIP1* abrogates *PGC-1α*-mediated induction of mitochondrial membrane potential and mitochondrial biogenesis [25]. Furthermore, at least 1/3 of NEMGs upregulated after *PGC-1α* induction in human osteoblast-like cells [28] were found to be *NRIP1* targets [23].

To assess that, among the Hsa21 transcription regulators, *NRIP1* was indeed the main dysregulator of mitochondrial gene expression, the Gene Expression Omnibus (GEO) repository (<http://www.ncbi.nlm.nih.gov/geo>) was screened for gene expression data related to the modulation of Hsa21 genes. The functional class scoring of the lists of genes dysregulated, when Hsa21 genes were individually overexpressed (GSE19836 experiment [29]), demonstrated that, among the Hsa21 transcription factors or regulators, only *NRIP1* was able to affect NEMG regulation with a cluster of 37 NEMGs downregulated after *NRIP1* overexpression [23].

We then demonstrated that *NRIP1* attenuation by siRNA in DS fibroblasts affected NEMG expression, increased *PGC-1α* expression and counteracted mitochondrial dysfunction in terms of ROS production, mitochondrial activity, mitochondrial calcium and ATP content [23].

These findings indicate that the Hsa21 gene *NRIP1* strongly contributes to the mitochondrial dysfunction observed in DS and suggest that the *NRIP1-PGC-1α* axis might represent a potential therapeutic target for restoring altered mitochondrial function in DS.

3.2.2. APP

Mitochondrial abnormalities and a decreased COX activity might also be induced by overproduction of beta-APP [30], although the TS1Cje mouse model, in which *APP* is not triplicated, also shows decreased mitochondrial function and ATP production [10]. Overexpression of APP induces mitochondrial oxidative stress and activates the intrinsic apoptotic cascade [31]. In addition, amyloid-β fragments, particularly Aβ42, exert direct toxic effects on cells, including Ca²⁺ dysregulation, mitochondrial dysfunction and induction of oxidative stress [32, 33]. APP protein has been demonstrated to progressively accumulate within mitochondrial matrix leading to increased free radicals and impaired mitochondrial metabolism [34]. In addition, APP have been shown to translocate into mitochondria when overexpressed in a human cortical neuronal cell line [35]. APP exerts synergistic effects with other Hsa21 genes [36].

3.2.3. SUMO3

It may affect mitochondrial function by modulating the *NRIP1* repressive activity [37]. SUMOylation also attenuates the transcriptional activity of *PGC-1α*, possibly by enhancing the interaction between *PGC-1α* and the corepressor *NRIP1* that alters its nuclear distribution [38]. *SUMO3* overexpression in DS could therefore be responsible for a concurrent improvement of *NRIP1* function and decrease of *PGC-1α* activity.

3.2.4. DYRK1A and DSCR1/RCAN1

The protein products of these genes interact functionally. Their increased dosage cooperatively leads to dysregulation of the signaling pathways that are controlled by NFAT family of transcription factors, with potential consequences for several organs and systems that are affected in DS individuals [39]. The two genes control *PGC-1α* activity via the calcineurin/NFAT pathway [40], namely through the binding of NFATc genes to the *PGC-1α* promoter [41]. Calcineurin is involved in the regulation of many cellular processes, including cardiac hypertrophy, skeletal-muscle development, synaptic plasticity and T-cell activation [39].

RCAN1, also known as calcipressin, has been found chronically overexpressed in the brain of both DS patients and sporadic AD patients [42]. *RCAN1* overexpression has been linked to oxidative stress and mitochondrial dysfunction [42–45] and is strictly related to calcium overloading [46], as it affects mitochondrial permeability transition pore (mPTP) function. *RCAN1*-induced mPTP opening leads to a series of consequences, including Ca²⁺ retention

incapability, massive swelling of mitochondria and rupture of the outer membrane [46]. In agreement with these data, deregulation of Ca^{2+} homeostasis and Ca^{2+} -mediated signaling has been described in cells derived from trisomic patients or in murine models of DS [47]. Mitochondrial Ca^{2+} concentration was found significantly higher in fibroblasts from DS feti [3], which also show swelled mitochondria with damaged membranes [4].

The overexpression of the brain-specific *RCAN1.1S* isoform in mice promotes dysregulation of dynamin-related protein 1 (*DRP1*), a protein that promotes mitochondrial fission [48]. Accordingly, *RCAN1* was found to induce mitochondrial autophagy in cardiomyocytes [49].

3.2.5. *SOD1*

The redox imbalance in DS has been long attributed to overexpression of Cu/Zn superoxide dismutase *SOD1*, whose levels are approximately 50% greater in cells from DS patients than in normal ones [50]. *SOD1*, the major *SOD* in mammalian cells, catalyzes the dismutation of superoxide radicals to H_2O_2 and O_2 and is an important antioxidant defense system [51].

3.2.6. *ETS-2*

Studies in transgenic mice showed that *ETS-2* overexpression induces apoptosis of thymus, spleen and brain cells [52]. Furthermore, *ETS-2* promotes the activation of a mitochondrial death pathway in DS neurons. Overexpression of *ETS-2* induces cytochrome c translocation to the cytoplasm and apoptotic features in normal human cortical neurons [53].

3.2.7. *ITSN1*

This gene regulates the mitochondrial apoptotic pathway in endothelial cells [54].

3.2.8. *PKNOX1/PREP1*

This gene, which encodes for a homeodomain transcription factor, is involved in embryonic development regulating the homeobox protein Pbx activity [55]. DS human fibroblasts that express higher levels of *PREP1* are more sensitive to genotoxic stress. *PREP1* demonstrated to regulate mitochondrial oxidative phosphorylation components. It directly binds to the promoter region of genes encoding mitochondrial components [56] and indirectly controls the stability of p160 Myb-binding protein, a powerful negative regulator of *PGC-1 α* activity [57]. In the muscle of *Prep1* ablated mice, *Pgc-1 α* expression was increased with consequent increasing in abundance of mitochondrial OXPHOS proteins and in citrate synthase activity together with an improved maximal oxidative capacity. Most important, *Prep1* ablation significantly increased the abundance of *Opa1* and *Mfn2*, two genes inducing mitochondrial fusion [56]. These results suggest that *PREP1* negatively regulates OXPHOS and mitochondrial network.

3.2.9. *BACH1*

This gene is a transcriptional regulator, which acts as hypoxia regulator by binding to antioxidant response elements of DNA thus inhibiting the transcription of specific genes involved

in cell stress response, including heme oxygenase-1 (HO-1). HO-1 and its partner, biliverdin reductase-A (BVR-A), are upregulated in response to oxidative stress. BACH1 protein was found decreased in DS brains, coupled with reduced induction of brain HO-1. This supports the hypothesis that the dysregulation of HO-1/BVR-A system contributes to the early increase of oxidative stress in DS and provides potential mechanistic pathways involved in the neurodegenerative process and AD development [58].

3.2.10. *S100B*

This gene codes for the b subunit of S100 proteins, a large family of calcium-binding proteins. The *S100B* homodimer is the major form in the mammalian brain. It can stimulate neurite extension [59] and plays a role in synaptogenesis [60], dendritic branching [61] and apoptosis [62]. *S100B* protein has long been suggested to be involved in glial cell activation and neuroinflammation [63]. Elevated brain *S100B* expression occurs in various disease states, including AD and DS. *S100B* plays an important role in neuroinflammation and in the regulation and maintenance of the serotonergic nervous system, with a particular focus on the hippocampus [64].

In vitro studies of DS fetal human neural precursors (HNP) demonstrated that *S100B* is constitutively overexpressed in these cells and that overexpression leads to increased ROS formation, activation of stress response kinases and increased programmed cell death. Further studies demonstrated that DS HNPs adopt more gliocentric progenitor phenotypes, if compared with euploid controls, with a consequent reduction in neuronogenesis [65].

3.3. Hsa21 miRNAs involved in mitochondrial phenotype

Hsa21 encodes several classes of non-coding RNAs, the most enriched being long non-coding RNAs, while miRNAs are the less represented [66]. The most recent annotation of miRNA database (miRBase, release 21) reports 29 miRNAs mapping to Hsa21. At least two of them, miR-155-5p and let-7c-5p, are possibly involved in mitochondrial function.

It was recently reported that the Hsa21 miR-155-5p affects mitochondrial biogenesis by targeting the mitochondrial transcription factor A (*TFAM*) [67], a gene that was found downregulated in trisomic hearts [1]. *TFAM* is a nuclear-encoded protein that controls the transcription and maintenance of mtDNA and therefore mitochondrial biogenesis.

Another Hsa21 miRNA potential candidate for mitochondrial anomalies is let-7c. By bioinformatics analysis, it appears to have several targets among genes that were found downregulated in trisomic fetal hearts and involved in mitochondrial function. Among these targets, *SLC25A4/ANT1* [68] appeared as a potential candidate for both mitochondrial dysfunction and congenital heart defects in DS. This gene functions as a gated pore that translocates ADP and ATP between cytoplasm and mitochondria, regulating the intracellular energetic balance. Furthermore, its dysregulation has been associated to mitochondrial cardiomyopathies [69] and its genetic inactivation results in mtDNA damage and ROS increase [8].

4. How mitochondrial dysfunction might affect DS clinical phenotype?

4.1. Muscle hypotonia

DS patients suffer from muscle hypotonia and altered motor coordination. In the Ts65Dn mice, the ultrastructural analysis of myofibrils showed mitochondrial structural changes [12, 70], whereas microarray analysis revealed that pathways involved in ATP biosynthesis, proteolysis, glucose and fat metabolism and neuromuscular transmission were dysregulated [12].

Skeletal muscle is particularly vulnerable to oxidative stress. The disruption of mitochondrial network towards fragmentation, together with mitochondrial dysfunction, is an essential step of the muscular atrophy programme in adult animals [71]. Conversely, inhibition of the mitochondrial fission inhibits muscle loss [72]. Furthermore, changes in mitochondrial morphology have been implicated in apoptosis as well as in the regulation of muscle metabolism [73].

It is worth noting that patients with DS have features of premature aging [74, 75] and exhibit a decrement in muscle strength if compared with euploid subjects, similar to what occurs in aged versus young persons [76]. It is, therefore, possible that muscle hypotonia and motor dysfunction in DS share some basic mechanisms with the progressive age-related decrease in skeletal muscle mass, strength and quality known as sarcopenia [77].

4.2. Intellectual disability and neurodegeneration

Increasing evidences are demonstrating that mitochondrial function is a key actor in the events that lead to intellectual disability and neurodegeneration in DS. Development of the DS brain is associated with decreased neuronal number and abnormal neuronal differentiation [78]. Patients with DS show higher levels of oxidative stress at all ages and apoptosis and generation of ROS are increased in human fetal DS neurons if compared with the general population [78, 79]. DS astrocytes and neuronal cultures [8, 9] as well as the brain of the Ts1Cje mouse model [10] show a decrease of mitochondrial membrane potential, ATP production and an increase of reactive oxygen species [10]. Mitochondrial bioenergetics and biogenesis are impaired during neural progenitor cell (NPC) proliferation in Ts65Dn cells [11]. Mitochondrial morphology was found consistently altered in TS21 astrocytes and neurons, which exhibit increased fragmentation of the mitochondrial network [13]. Mitochondrial function, fission-fusion mechanisms, biogenesis and degradation are critical for synaptogenesis, Ca^{2+} buffering, axonal transport and bioenergetics [80]. Functionally and structurally damaged mitochondria do not produce sufficient ATP and are more prone in producing pro-apoptotic factors and ROS [81], which also represent an early stage in neurodegenerative process [82]. An increased risk for AD manifests in most of DS individuals starting from 40 years of age [83, 84]. The similarity of neurodegenerative processes between DS and Alzheimer disease (AD) and the high prevalence of AD in DS patients suggest that AD and DS share common brain alterations possibly due to similar molecular pathways involved in the pathogenesis, such as mitochondrial dysfunction and oxidative stress [85]. Energy depletion and

oxidative stress can also induce amyloidogenic changes in A β PP processing [86]. Busciglio et al. [9] demonstrated that there is a marked alteration in A β PP processing and A β trafficking in cortical DS astrocytes and neurons, similar to those induced in normal human astrocytes by inhibition of mitochondrial energy metabolism.

It is important to note that neurodegenerative diseases, such as AD, PD and HD, show alterations of mitochondrial function and fusion and/or fission processes very similar to those observed in DS [82, 87] as well as a similar dysregulation of mitochondria-related genes most of which are target of the *NRIP1/PGC-1 α* axis [23].

4.3. Heart defects

DS is a major cause of congenital heart defects (CHD), mostly derived from endocardial cushion anomalies, such as atrioventricular septal defects, ventricular septal defects and tetralogy of Fallot [88, 89].

Transcriptome analysis of human fetal heart tissues from DS subjects has shown a global significant downregulation of NEMGs. Genes from all five complexes were downregulated, suggesting that the corresponding proteins and enzymatic activities might be reduced and that the mitochondrial function could be consequently impaired [1]. When mitochondrial phenotype was analyzed in fibroblasts from the same subjects, a more pronounced chronic pro-oxidative state was demonstrated in DS fetuses with congenital heart defects if compared with feti without cardiopathy [3]. Significant differences in mitochondrial respiration, complex I activity and ROS production were observed, suggesting a relationship between mitochondrial function and cardiac phenotype [3]. These alterations might be harbingers of the heart defects associated with Hsa21 trisomy, which could be based on elusive mechanisms involving genetic variability, environmental factors and/or stochastic events [1].

Searching for a link between heart development and mitochondria, the focus falls on the Hsa21 genes *DYRK1A* and *RCAN1*, which play a role in the calcineurin/NFAT pathway [40] and are believed to affect both mitochondrial activity and morphology during heart development [90, 91]. *DYRK1A* and *RCAN1* are involved in regulating the levels of NFATc phosphorylation. The calcineurin/NFAT signaling pathway is known to be a critical regulator of organogenesis [92] and the NFATc transcription factors are transiently expressed in the endocardial cushions during heart septation [91]. The *DSCR1* and *DYRK1A* genes, both mapping on Hsa21 within the critical region for DS, act synergistically to prevent nuclear translocation of NFATc transcription factors and may cause their downregulation [40]. Even modest overexpression of *DYRK1A* decreases NFATc protein activity and levels and may induce vascular and cardiac defects [40]. The inhibition of the mitochondrial activity in *Nfatc3*^{-/-}*Nfatc4*^{-/-} cardiomyocytes [90] suggests that the calcineurin/NFAT pathway affects mitochondrial activity during heart development. *Nfatc*-null mice show phenotypic anomalies that resemble those observed in human DS and 65% of *Nfatc1-4*-null mice have endocardial cushion defects [40]. In human DS fetal fibroblasts and hearts, NFATc3 and NFATc4 were found significantly downregulated, whereas *DYRK1A* and *RCAN1* were overexpressed possibly due to dosage effect [1, 3].

In addition to congenital heart defects, DS subject may develop ventricular hypertrophy during the post-natal life possibly as a result of reduced mitochondrial electron-transport chain activity and oxygen consumption. Alterations in mitochondrial function observed in right ventricular cardiac hypertrophy are mainly attributed to complex I dysfunction [93]. *NRIP1*-dependent repression of mitochondria related genes may be involved in the pathogenesis of this defect. The overexpression of this gene in a transgenic mouse demonstrated to cause cardiac hypertrophy [94].

Also the Hsa21 miR-155, a known repressor of *TFAM* gene [67], was uncovered as an inducer of pathological cardiomyocyte hypertrophy, suggesting that inhibition of endogenous miR-155 might have clinical potential to suppress cardiac hypertrophy and heart failure [95]. MiR-155 is overexpressed in fetal heart tissue possibly due to dosage effect [68].

4.4. Type 2 diabetes and obesity

Children with DS have an increased risk of developing endocrine disorders such as type 2 diabetes and obesity [96]. The hypothesis that prominent features of type 2 diabetes and the condition of obesity are caused by mitochondrial dysfunction and by an impaired bioenergetics capacity is definitively emerging [97]. Given the important role that mitochondria play for bioenergetics support of signal transduction, fat oxidation and substrate transport, an impairment of electron transport chain activity may have particular relevance to the pathogenesis of insulin resistance in type 2 diabetes [98]. This hypothesis is substantiated by two evidences: (i) a disproportionately large reduction of electron transport chain activity has been observed in the subsarcolemmal mitochondrial fraction in type 2 diabetic and obese subjects if compared with unaffected volunteers and (ii) mitochondria from human skeletal muscle were found to be smaller and to have reduced activity of complex I in both type 2 diabetes and obesity [99].

Interestingly, the Hsa21 corepressor gene *NRIP1* and its target *PGC-1 α* play key roles in the transcriptional regulation of genes involved in energy homeostasis. The expression and promoter activity of CIDEA, an important regulatory factor in adipose cell function and obesity, is repressed by *NRIP1* and induced by *PGC-1 α* [100]. These genes are also involved in glucose uptake by affecting the regulation of both transcription and subcellular localization of the insulin-sensitive glucose transporter *GLUT4* [101]. This evidence suggested that *NRIP1* might be a potential therapeutic target in the treatment of insulin resistance in obese and type 2 diabetic patients [101]. Accordingly, mice lacking *Nrip1* are lean, show resistance to high-fat diet-induced obesity and have increased oxygen consumption [102].

Some evidences support the role of an altered mitochondrial dynamics in obesity. It is known that obesity in both humans and mice is associated with reduced *Mfn2* expression and therefore with a defective mitochondrial fusion machinery [103]. Furthermore, an altered proteolytic processing of the GTPase *OPA1* in humans is associated with insulin resistance [104].

4.5. Immune disorders

Children with DS demonstrate an increased susceptibility to infections, usually of the upper respiratory tract [105–107], and autoimmune disorders, including hypothyroidism [108] and

celiac disease [109, 110]. The abnormalities of the immune system associated with DS include alteration of B and T-cell number, with marked decrease of naive lymphocytes; abnormal thymus functions and development; impaired mitogen-induced T cell proliferation; reduced specific antibody responses to immunizations and defects of neutrophil chemotaxis [111, 112]. The rates of lymphocyte respiration in the children with DS were found slower than in the control group [113].

Important roles of mitochondrial dynamics in the immune system physiopathology have been recently demonstrated. The first evidence is that mitochondria transportation during lymphocyte migration requires mitochondrial fission [114]. The second is that mitochondrial remodeling works as a signaling mechanism that instructs T cell metabolic programming [115]. This theory arises from the demonstration that T effector (TE) cells show a fragmented network with punctuate mitochondria, whereas T memory (TM) cells show fused networks. Accordingly, in transgenic *Opa1^{-/-}* mice, TM lymphocytes show a decreased survival associated with altered cristae structure and decreased spare respiratory capacity. In addition, TE cells could be shifted to a TM fate depending upon changes of mitochondrial dynamics. These data suggest that, by altering cristae morphology, fusion in TM cells configures electron transport chain (ETC) complex associations favoring OXPHOS and fatty acid oxidation, whereas fission in TE cells leads to cristae expansion, reducing ETC efficiency and promoting aerobic glycolysis [115].

5. Therapeutic approaches to improve mitochondrial function in DS

5.1. Possible therapeutic targets

As mitochondrial dysfunction might concur to determine DS mental retardation and other health problems, we might expect that counteracting the mitochondrial defects will improve and/or prevent some aspects of the DS phenotype.

The few clinical trials so far undertaken to restore mitochondrial function in DS subjects using antioxidants and nutraceuticals have yielded either poor or discordant outcomes [116, 117]. Better results were obtained on learning and memory in the mouse model Ts65Dn using pentylenetetrazole, memantine, fluoxetine, lithium, epigallocatechin-3-gallate (EGCG) and antioxidants such as vitamin E [118]. Also in this case, the clinical trials have not yielded the expected results.

The key role of *PGC-1α* as a modulator of mitochondrial biogenesis and respiratory function suggests that therapeutic approach on mitochondrial dysfunction in DS could be based either on *PGC-1α* activators, which have been tested in mouse models for other disease [119–122], or on PPAR γ agonists, which demonstrated to attenuate mitochondrial dysfunction in AD mouse models [123–126].

It is known that *PGC-1α* activity is mainly controlled by PPARs, AMP-activated kinases (AMPKs) and the NAD-dependent deacetylase SIRT1 [127]. Direct phosphorylation by AMPK promotes *PGC-1α*-dependent induction at the *PGC-1α* promoter level [122], whereas *SIRT1*

stimulates *PGC-1α* activity through deacetylation, thereby inducing mitochondrial biogenesis [119]. Pharmacological activators for these proteins, such as metformin, via AMPK induction, and resveratrol, via *SIRT1* induction, have been tested in mouse models for neurodegenerative diseases in which mitochondrial alterations play a central role such as AD, Parkinson's disease and Huntington's disease [120–122].

A comprehensive analysis was performed to evaluate in vitro the effects of potential *PGC-1α* activating drugs [128]. The authors pharmaceutically targeted the PPARs (bezafibrate, rosiglitazone), AMPK (AICAR, metformin) and SIRT1 (resveratrol) pathways in HeLa cells, neuronal cells and *PGC-1α*-deficient MEFs demonstrating tissue-specific effects of these drugs in modulating mitochondrial processes and cellular stress programs. All the observed effects were clearly dependent on *PGC-1α* modulation.

5.2. Advances in preclinical and clinical therapeutic approaches

5.2.1. Antioxidants

Most of the clinical trials so far undertaken in DS patients are based on antioxidant nutrients or vitamin administration to scavenge oxygen-derived free radicals [129, 130].

A study in which a mixture of antioxidants (selenium, zinc, vitamin A, vitamin E and vitamin C) and/or folinic acid was administered as supplementation to children with DS aged under 7 months for about 18 months provided no evidence to support the use of these supplements as this supplementation did not affect oxidative stress [131]. An interesting comment to this study was "This is perhaps not surprising because differences between foetuses with Down's syndrome and unaffected foetuses can be identified after only 11 weeks gestation, implying that by 7 months of age, any damage may already have been done" [132]. Vitamin E administration in a recent study did not demonstrate to slow the progression of cognitive deterioration in older individuals with DS [133].

Coenzyme Q₁₀ (CoQ₁₀) is a bioactive quinone ubiquitous in the organism, involved in mitochondrial bioenergetics, with a known role as a lipophilic antioxidant [134]. CoQ₁₀ supplementation to 10 patients with TS21 for 3 months demonstrated that the pro-oxidant state in plasma of children with trisomy 21, as assessed by ubiquinol-10:total CoQ₁₀ ratio, may be normalized with ubiquinol-10 supplementation [130]. The authors concluded that further studies would be needed to determine whether correction of this oxidant imbalance improves clinical outcomes of children with trisomy 21 but no results in this direction have yet been communicated.

Overall, these results show that antioxidant supplementation is safe but it does neither improve the cognitive performance nor dementia in DS patients.

5.2.2. Melatonin

The antioxidant properties of melatonin induced to study plasma melatonin concentrations in a small group of children with DS [135]. Plasma melatonin concentrations were lower in DS

subjects than in age-matched controls. The authors concluded that this constituted an added oxidative risk to children with DS. Melatonin treatment has demonstrated to induce anti-oxidant and antiaging effects in the hippocampus of adult Ts65Dn mice [136]. Unfortunately, even though this treatment attenuated the oxidative damage and cellular senescence in the brain [136], pre-and post-natal melatonin administration in an additional study partially regulated brain oxidative stress but did not demonstrate to improve cognitive or histological alterations in the same DS mouse model [137].

5.2.3. Epigallocatechin-3-gallate (EGCG)

EGCG—a member of a natural polyphenol family—is a mitochondrial-targeted molecule displaying a selective antiapoptotic effect against inducers of mitochondrial oxidative stress in a variety of neuronal cell types [138]. EGCG has been found to prevent mitochondrial deterioration in aged rat brain [139], reduce cerebral amyloidosis [140] and correct amyloid-induced mitochondrial dysfunction in a transgenic mice model of Alzheimer disease [141].

EGCG modulates key regulators of mitochondrial metabolism such as Sirt1 activity [142] and cAMP levels [143, 144] in addition to being a specific and safe inhibitor of the Hsa21 gene *DYRK1A*, a kinase protein involved in brain development and in the control of synaptic plasticity [145]. This makes EGCG an interesting candidate drug for the treatment of DS phenotype.

A therapeutic benefit on mitochondrial activity by EGCG has been demonstrated in cellular and murine model of DS. Indeed EGCG treatment renews the capacity of DS cells to produce energy by mitochondrial OXPHOS and to prevent mitochondrial ROS overproduction [146]. The treatment of neural progenitor cells, isolated from the hippocampus of Ts65Dn, by EGCG reactivates mitochondria bioenergetics and biogenesis and promotes neural progenitor cell proliferation [11]. On the other hand, *in vivo* studies demonstrated that young adults with DS treated with EGCG exhibit some cognitive benefits, although these effects disappear with time [147]. Furthermore, the treatment carried out in the mouse model Ts65dn in the neonatal period rescues numerous trisomy-linked brain alterations. However, even during this critical time window for hippocampal development, EGCG does not elicit enduring effects on the hippocampal physiology [148].

A further study showed that a temporally specific prenatal EGCG treatment improved some craniofacial dysmorphology associated with DS in Ts65Dn embryos and mice. EGCG in particular improved neural crest cells (NCC)-related deficits in proliferation and migration *in vitro* in mandibular precursor cells from Ts65Dn E9.5 embryos. *In vivo* treatment with EGCG at E7 and E8, around the time of the developing NCC deficit, appeared to improve some of the NCC embryonic dysmorphology in Ts65Dn E9.5 embryos [149]. However, a long-lasting EGCG treatment at a lower dose (E0–E9) did not have the same corrective effects.

More recently, the same authors demonstrated that a higher dose of EGCG in Ts65Dn mice and euploid littermates failed to improve cognitive deficits; EGCG also produced several detrimental effects on skeleton in both genotypes [150].

In conclusion, EGCG stimulates mitochondrial biogenesis and promotes oxidative phosphorylation through cAMP/PKA- and sirtuin-dependent mechanism [146], and also, at higher concentrations, it promotes apoptosis through mitochondrial damage, membrane depolarization and cytochrome c release [151, 152]. All these results suggest that timing and dosage of EGCG treatment are important and have to be optimized in treating DS-related phenotypes.

5.2.4. Resveratrol

Resveratrol (RSV), a natural polyphenolic compound found in a wide variety of plant species, induces expression of genes involved in mitochondrial biogenesis, oxidative phosphorylation and endogenous antioxidant defense by modulation of cell signaling pathways that control cell homeostasis. RSV treatment protected mice against diet-induced obesity and insulin resistance. This effect was largely explained by an RSV-mediated decrease in *PGC-1 α* acetylation and an increase in *PGC-1 α* activity [153]. RSV increased the mean life expectancy and maximal lifespan in a mouse model of sporadic and age-related AD. RSV-supplemented animals showed increased Sirt1 expression and consequent downregulation of apoptotic protein p53 in the cortex and hippocampus. Also, p-AMPK in the cortex and total AMPK in the hippocampus were increased [153]. Although thousands of research papers have been published related to RSV pharmacological activities in many diseases, only one study has been performed on the effect of this polyphenol in DS [11]. The authors of the study conclude that RSV can sustain and enhance mitochondrial functions by upregulating *PGC1 α /Sirt1/AMPK* axis and promote neural precursor proliferation from Ts65Dn. They suggest resveratrol as a new drug to be tested *in vivo* as potential therapeutic tool to promote mitochondrial functions, accelerate neurogenesis and ultimately counteract some of the DS clinical features [11].

5.2.5. Metformin

The effects of the biguanide metformin on mitochondrial function have been investigated in human trisomic fibroblasts [4]. Metformin demonstrated to induce both the expression and the activity of *PGC-1 α* and to upregulate its target genes *NRF-1* and *TFAM*, thus promoting mitochondrial biogenesis. The drug enhanced ATP production in treated cells and improved overall mitochondrial activity. Most interestingly, metformin treatment counteracted mitochondrial fission observed in trisomic fibroblasts, inducing the formation of a mitochondrial network with a branched and elongated tubular morphology (**Figure 2**) and regulating the expression of genes involved in the fission/fusion machinery, namely *OPA1* and *MFN2* [4].

Metformin has shown to improve cognition in patients with mild cognitive impairment and AD [154]. There were no serious adverse events related to its administration.

Metformin is a drug commonly used as a hypoglycemic agent in type 2 diabetes because it inactivates gluconeogenesis [155]. Metformin activates AMPK in the liver and muscles, causing the phosphorylation and the consequent activation of *PGC-1 α* , and upregulates SIRT1 that in turn activates *PGC-1 α* by deacetylation [155].

Moreover, it has been found that metformin promotes neurogenesis in rodent and human neural precursors and enhances spatial memory formation in normal adult mouse [156].

Metformin is an already registered drug with limited side effects that can be safely administered during pregnancy and crosses both the placental and blood-brain barrier [157, 158]. For these characteristics, it could be immediately introduced in human therapeutic protocols.

6. Conclusions

The study of candidate pathogenic mechanisms in DS is helping scientists to develop more appropriate therapeutic solutions for the treatment of this still untreatable genetic disorder.

A long way has been paved in this direction as we have already gained important knowledge about the importance of bioenergetics mechanisms in determining the DS phenotype and the roles played by Hsa21 genes in this scenario.

The working hypothesis is that counteracting the mitochondrial defect in DS may improve the neurological phenotype and prevent DS-associated pathologies, such as Alzheimer's disease, type 2 diabetes, obesity and hypertrophic cardiopathy, thus providing a better quality of life for DS individuals and their families.

Impaired energy metabolism, defect of mitochondrial enzyme activities and abnormalities of mitochondrial respiration are common characteristics of neurodegenerative conditions [20]. On these premises, restoring the mitochondrial function could represent also a promising strategy to limit the progression of neurodegenerative diseases and even to delay some common aging processes.

Should any of these drugs, already registered for different purposes, demonstrate to be effective, they could be immediately introduced in human therapeutic protocols possibly along with specific therapies aimed at restoring cognitive functions.

Author details

Antonella Izzo, Nunzia Mollo, Rita Cicatiello, Rita Genesio, Simona Paladino, Anna Conti* and Lucio Nitsch

*Address all correspondence to: anconti@unina.it

Department of Molecular Medicine and Medical Biotechnology, University Federico II, Naples, Italy

References

- [1] Conti A, Fabbrini F, D'Agostino P, Negri R, Greco D, Genesio R, et al. Altered expression of mitochondrial and extracellular matrix genes in the heart of human fetuses with chromosome 21 trisomy. *BMC Genomics*. 2007;8:268

- [2] Mao R, Wang X, Spitznagel EL Jr, Frelin LP, Ting JC, Ding H, et al. Primary and secondary transcriptional effects in the developing human Down syndrome brain and heart. *Genome Biology*. 2005;6(13):R107
- [3] Piccoli C, Izzo A, Scrima R, Bonfiglio F, Manco R, Negri R, et al. Chronic pro-oxidative state and mitochondrial dysfunctions are more pronounced in fibroblasts from Down syndrome foeti with congenital heart defects. *Human Molecular Genetics*. 2013;22(6):1218-1232
- [4] Izzo A, Nitti M, Mollo N, Paladino S, Procaccini C, Faicchia D, et al. Metformin restores the mitochondrial network and reverses mitochondrial dysfunction in Down syndrome cells. *Human Molecular Genetics*. 2017
- [5] Valenti D, Tullo A, Caratozzolo MF, Merafina RS, Scartezzini P, Marra E, et al. Impairment of F1F0-ATPase, adenine nucleotide translocator and adenylyl kinase causes mitochondrial energy deficit in human skin fibroblasts with chromosome 21 trisomy. *The Biochemical Journal*. 2010;431(2):299-310
- [6] Valenti D, Manente GA, Moro L, Marra E, Vacca RA. Deficit of complex I activity in human skin fibroblasts with chromosome 21 trisomy and overproduction of reactive oxygen species by mitochondria: Involvement of the cAMP/PKA signalling pathway. *The Biochemical Journal*. 2011;435(3):679-688
- [7] Kim SH, Vlkolinsky R, Cairns N, Fountoulakis M, Lubec G. The reduction of NADH ubiquinone oxidoreductase 24- and 75-kDa subunits in brains of patients with Down syndrome and Alzheimer's disease. *Life Sciences*. 2001;68(24):2741-2750
- [8] Arbuzova S, Hutchin T, Cuckle H. Mitochondrial dysfunction and Down's syndrome. *BioEssays: News and Reviews in Molecular, Cellular and Developmental Biology*. 2002;24(8):681-684
- [9] Busciglio J, Pelsman A, Wong C, Pigino G, Yuan M, Mori H, et al. Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. *Neuron*. 2002;33(5):677-688
- [10] Shukkur EA, Shimohata A, Akagi T, Yu W, Yamaguchi M, Murayama M, et al. Mitochondrial dysfunction and tau hyperphosphorylation in Ts1Cje, a mouse model for Down syndrome. *Human Molecular Genetics*. 2006;15(18):2752-2762
- [11] Valenti D, de Bari L, de Rasmo D, Signorile A, Henrion-Caude A, Contestabile A, et al. The polyphenols resveratrol and epigallocatechin-3-gallate restore the severe impairment of mitochondria in hippocampal progenitor cells from a Down syndrome mouse model. *Biochimica et Biophysica Acta*. 2016;1862(6):1093-1104
- [12] Cowley PM, Keschlacy S, Middleton FA, DeRuisseau LR, Fernhall B, Kanaley JA, et al. Functional and biochemical characterization of soleus muscle in Down syndrome mice: Insight into the muscle dysfunction seen in the human condition. *American Journal of Physiology Regulatory, Integrative and Comparative Physiology*. 2012;303(12):R1251-R1260

- [13] Helguera P, Seiglie J, Rodriguez J, Hanna M, Helguera G, Busciglio J. Adaptive downregulation of mitochondrial function in down syndrome. *Cell Metabolism*. 2013;17(1):132-140
- [14] Tanaka A, Cleland MM, Xu S, Narendra DP, Suen DF, Karbowski M, et al. Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by Parkin. *The Journal of Cell Biology*. 2010;191(7):1367-1380
- [15] Westermann B. Mitochondrial fusion and fission in cell life and death. *Nature Reviews Molecular Cell Biology*. 2010;11(12):872-884
- [16] Fischer F, Hamann A, Osiewacz HD. Mitochondrial quality control: An integrated network of pathways. *Trends in Biochemical Sciences*. 2012;37(7):284-292
- [17] Golpich M, Amini E, Mohamed Z, Azman Ali R, Mohamed Ibrahim N, Ahmadiani A. Mitochondrial dysfunction and biogenesis in neurodegenerative diseases: Pathogenesis and treatment. *CNS Neuroscience & Therapeutics*. 2017;23(1):5-22
- [18] Leone TC, Lehman JJ, Finck BN, Schaeffer PJ, Wende AR, Boudina S, et al. PGC-1alpha deficiency causes multi-system energy metabolic derangements: Muscle dysfunction, abnormal weight control and hepatic steatosis. *PLoS Biology*. 2005;3(4):e101
- [19] Scarpulla RC. Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. *Biochimica et Biophysica Acta*. 2011;1813(7):1269-1278
- [20] Petrozzi L, Ricci G, Giglioli NJ, Siciliano G, Mancuso M. Mitochondria and neurodegeneration. *Bioscience Reports*. 2007;27(1-3):87-104
- [21] Vilardell M, Rasche A, Thormann A, Maschke-Dutz E, Perez-Jurado LA, Lehrach H, et al. Meta-analysis of heterogeneous Down syndrome data reveals consistent genome-wide dosage effects related to neurological processes. *BMC Genomics*. 2011;12:229
- [22] Sturgeon X, Le T, Ahmed MM, Gardiner KJ. Pathways to cognitive deficits in Down syndrome. *Progress in Brain Research*. 2012;197:73-100
- [23] Izzo A, Manco R, Bonfiglio F, Cali G, De Cristofaro T, Paternani S, et al. NRIP1/RIP140 siRNA-mediated attenuation counteracts mitochondrial dysfunction in Down syndrome. *Human Molecular Genetics*. 2014;23(16):4406-4419
- [24] Fritah A, Christian M, Parker MG. The metabolic coregulator RIP140: An update. *American Journal of Physiology. Endocrinology and Metabolism*. 2010;299(3):E335-E340
- [25] Chen Y, Wang Y, Chen J, Chen X, Cao W, Chen S, et al. Roles of transcriptional corepressor RIP140 and coactivator PGC-1alpha in energy state of chronically infarcted rat hearts and mitochondrial function of cardiomyocytes. *Molecular and Cellular Endocrinology*. 2012;362(1-2):11-18
- [26] Robinson-Rechavi M, Escriva Garcia H, Laudet V. The nuclear receptor superfamily. *Journal of Cell Science*. 2003;116(Pt 4):585-586
- [27] Lin J, Handschin C, Spiegelman BM. Metabolic control through the PGC-1 family of transcription coactivators. *Cell Metabolism*. 2005;1(6):361-370

- [28] Schreiber SN, Emter R, Hock MB, Knutti D, Cardenas J, Podvinec M, et al. The estrogen-related receptor alpha (ERRalpha) functions in PPARgamma coactivator 1alpha (PGC-1alpha)-induced mitochondrial biogenesis. *Proceedings of the National Academy of Sciences of the United States of America*. 2004;**101**(17):6472-6477
- [29] De Cegli R, Romito A, Iacobacci S, Mao L, Lauria M, Fedele AO, et al. A mouse embryonic stem cell bank for inducible overexpression of human chromosome 21 genes. *Genome Biology*. 2010;**11**(6):R64
- [30] Askanas V, McFerrin J, Baque S, Alvarez RB, Sarkozi E, Engel WK. Transfer of beta-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle. *Proceedings of the National Academy of Sciences of the United States of America*. 1996;**93**(3):1314-1319
- [31] Bartley MG, Marquardt K, Kirchhof D, Wilkins HM, Patterson D, Linseman DA. Overexpression of amyloid-beta protein precursor induces mitochondrial oxidative stress and activates the intrinsic apoptotic cascade. *Journal of Alzheimer's Disease: JAD*. 2012;**28**(4):855-868
- [32] Chen JX, Yan SS. Role of mitochondrial amyloid-beta in Alzheimer's disease. *Journal of Alzheimer's Disease: JAD*. 2010;**20**(Suppl 2):S569-S578
- [33] Demuro A, Parker I, Stutzmann GE. Calcium signaling and amyloid toxicity in Alzheimer disease. *The Journal of Biological Chemistry*. 2010;**285**(17):12463-12468
- [34] Manczak M, Mao P, Calkins MJ, Cornea A, Reddy AP, Murphy MP, et al. Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons. *Journal of Alzheimer's Disease: JAD*. 2010;**20**(Suppl 2):S609-S631
- [35] Anandatheerthavarada HK, Biswas G, Robin MA, Avadhani NG. Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells. *The Journal of Cell Biology*. 2003;**161**(1):41-54
- [36] Lu J, Esposito G, Scuderi C, Steardo L, Delli-Bovi LC, Hecht JL, et al. S100B and APP promote a gliocentric shift and impaired neurogenesis in Down syndrome neural progenitors. *PLoS One*. 2011;**6**(7):e22126
- [37] Rytinki MM, Palvimo JJ. SUMOylation modulates the transcription repressor function of RIP140. *The Journal of Biological Chemistry*. 2008;**283**(17):11586-11595
- [38] Rytinki MM, Palvimo JJ. SUMOylation attenuates the function of PGC-1alpha. *The Journal of Biological Chemistry*. 2009;**284**(38):26184-26193
- [39] de la Luna S, Estivill X. Cooperation to amplify gene-dosage-imbalance effects. *Trends in Molecular Medicine*. 2006;**12**(10):451-454
- [40] Arron JR, Winslow MM, Polleri A, Chang CP, Wu H, Gao X, et al. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. *Nature*. 2006;**441**(7093):595-600

- [41] Handschin C, Rhee J, Lin J, Tarr PT, Spiegelman BM. An autoregulatory loop controls peroxisome proliferator-activated receptor gamma coactivator 1alpha expression in muscle. *Proceedings of the National Academy of Sciences of the United States of America*. 2003;**100**(12):7111-7116
- [42] Wu Y, Song W. Regulation of RCAN1 translation and its role in oxidative stress-induced apoptosis. *FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology*. 2013;**27**(1):208-221
- [43] Chang KT, Min KT. *Drosophila melanogaster* homolog of Down syndrome critical region 1 is critical for mitochondrial function. *Nature Neuroscience*. 2005;**8**(11):1577-1585
- [44] Peiris H, Dubach D, Jessup CF, Unterweger P, Raghupathi R, Muyderman H, et al. RCAN1 regulates mitochondrial function and increases susceptibility to oxidative stress in mammalian cells. *Oxidative Medicine and Cellular Longevity*. 2014;**2014**:520316
- [45] Ermak G, Sojitra S, Yin F, Cadena E, Cuervo AM, Davies KJ. Chronic expression of RCAN1-1L protein induces mitochondrial autophagy and metabolic shift from oxidative phosphorylation to glycolysis in neuronal cells. *The Journal of Biological Chemistry*. 2012;**287**(17):14088-14098
- [46] Sun X, Wu Y, Herculano B, Song W. RCAN1 overexpression exacerbates calcium overloading-induced neuronal apoptosis. *PLoS One*. 2014;**9**(4):e95471
- [47] Yamato F, Takaya J, Yasuhara A, Teraguchi M, Ikemoto Y, Kaneko K. Elevated intracellular calcium in neutrophils in patients with Down syndrome. *Pediatrics International: Official Journal of the Japan Pediatric Society*. 2009;**51**(4):474-477
- [48] Wong H, Levenga J, Cain P, Rothermel B, Klann E, Hoeffer C. RCAN1 overexpression promotes age-dependent mitochondrial dysregulation related to neurodegeneration in Alzheimer's disease. *Acta Neuropathologica*. 2015;**130**(6):829-843
- [49] Duan H, Li Y, Yan L, Yang H, Wu J, Qian P, et al. Rcan1-1L overexpression induces mitochondrial autophagy and improves cell survival in angiotensin II-exposed cardiomyocytes. *Experimental Cell Research*. 2015;**335**(1):99-106
- [50] Groner Y, Elroy-Stein O, Avraham KB, Schickler M, Knobler H, Minc-Golomb D, et al. Cell damage by excess CuZnSOD and Down's syndrome. *Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie*. 1994;**48**(5-6):231-240
- [51] Fridovich I. Superoxide radical and superoxide dismutases. *Annual Review of Biochemistry*. 1995;**64**:97-112
- [52] Wolvetang EJ, Wilson TJ, Sanij E, Busciglio J, Hatzistavrou T, Seth A, et al. ETS2 overexpression in transgenic models and in Down syndrome predisposes to apoptosis via the p53 pathway. *Human Molecular Genetics*. 2003;**12**(3):247-255
- [53] Helguera P, Pelsman A, Pigino G, Wolvetang E, Head E, Busciglio J. ets-2 promotes the activation of a mitochondrial death pathway in Down's syndrome neurons. *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience*. 2005;**25**(9):2295-2303

- [54] Predescu SA, Predescu DN, Knezevic I, Klein IK, Malik AB. Intersectin-1s regulates the mitochondrial apoptotic pathway in endothelial cells. *The Journal of Biological Chemistry*. 2007;**282**(23):17166-17178
- [55] Ferretti E, Villaescusa JC, Di Rosa P, Fernandez-Diaz LC, Longobardi E, Mazzieri R, et al. Hypomorphic mutation of the TALE gene Prep1 (pKnox1) causes a major reduction of Pbx and Meis proteins and a pleiotropic embryonic phenotype. *Molecular and Cellular Biology*. 2006;**26**(15):5650-5662
- [56] Kanzleiter T, Rath M, Penkov D, Puchkov D, Schulz N, Blasi F, et al. Pknox1/Prep1 regulates mitochondrial oxidative phosphorylation components in skeletal muscle. *Molecular and Cellular Biology*. 2014;**34**(2):290-298
- [57] Fan M, Rhee J, St-Pierre J, Handschin C, Puigserver P, Lin J, et al. Suppression of mitochondrial respiration through recruitment of p160 myb binding protein to PGC-1alpha: Modulation by p38 MAPK. *Genes & Development*. 2004;**18**(3):278-289
- [58] Di Domenico F, Pupo G, Mancuso C, Barone E, Paolini F, Arena A, et al. Bach1 over-expression in Down syndrome correlates with the alteration of the HO-1/BVR-a system: Insights for transition to Alzheimer's disease. *Journal of Alzheimer's Disease: JAD*. 2015;**44**(4):1107-1120
- [59] Marshak DR, Pena LA. Potential role of S100 beta in Alzheimer's disease: An hypothesis involving mitotic protein kinases. *Progress in Clinical and Biological Research*. 1992;**379**:289-307
- [60] Muller CM, Akhavan AC, Bette M. Possible role of S-100 in glia-neuronal signalling involved in activity-dependent plasticity in the developing mammalian cortex. *Journal of Chemical Neuroanatomy*. 1993;**6**(4):215-227
- [61] Yan W, Wilson CC, Haring JH. 5-HT1a receptors mediate the neurotrophic effect of serotonin on developing dentate granule cells. *Brain Research Developmental Brain Research*. 1997;**98**(2):185-190
- [62] Mariggio MA, Fulle S, Calissano P, Nicoletti I, Fano G. The brain protein S-100ab induces apoptosis in PC12 cells. *Neuroscience*. 1994;**60**(1):29-35
- [63] Allore R, O'Hanlon D, Price R, Neilson K, Willard HF, Cox DR, et al. Gene encoding the beta subunit of S100 protein is on chromosome 21: Implications for Down syndrome. *Science*. 1988;**239**(4845):1311-1313
- [64] Shapiro LA, Bialowas-McGoey LA, Whitaker-Azmitia PM. Effects of S100B on serotonergic plasticity and neuroinflammation in the hippocampus in down syndrome and Alzheimer's disease: Studies in an S100B overexpressing mouse model. *Cardiovascular Psychiatry and Neurology*. 2010;**2010**
- [65] Esposito G, Imitola J, Lu J, De Filippis D, Scuderi C, Ganesh VS, et al. Genomic and functional profiling of human Down syndrome neural progenitors implicates S100B and aquaporin 4 in cell injury. *Human Molecular Genetics*. 2008;**17**(3):440-457

- [66] Letourneau A, Antonarakis SE. Genomic determinants in the phenotypic variability of Down syndrome. *Progress in Brain Research*. 2012;**197**:15-28
- [67] Quinones-Lombrana A, Blanco JG. Chromosome 21-derived hsa-miR-155-5p regulates mitochondrial biogenesis by targeting Mitochondrial Transcription Factor A (TFAM). *Biochimica et Biophysica Acta*. 2015;**1852**(7):1420-1427
- [68] Izzo A, Manco R, de Cristofaro T, Bonfiglio F, Cicatiello R, Mollo N, et al. Over-expression of chromosome 21 miRNAs may affect mitochondrial function in the hearts of Down syndrome fetuses. *International Journal of Genomics*. 2017 In press
- [69] Tokumaru S, Suzuki M, Yamada H, Nagino M, Takahashi T. Let-7 regulates Dicer expression and constitutes a negative feedback loop. *Carcinogenesis*. 2008;**29**(11):2073-2077
- [70] Cisterna B, Costanzo M, Scherini E, Zancanaro C, Malatesta M. Ultrastructural features of skeletal muscle in adult and aging Ts65Dn mice, a murine model of Down syndrome. *Muscles, Ligaments and Tendons Journal*. 2013;**3**(4):287-294
- [71] Romanello V, Guadagnin E, Gomes L, Roder I, Sandri C, Petersen Y, et al. Mitochondrial fission and remodelling contributes to muscle atrophy. *The EMBO Journal*. 2010;**29**(10):1774-1785
- [72] Romanello V, Sandri M. Mitochondrial biogenesis and fragmentation as regulators of muscle protein degradation. *Current Hypertension Reports*. 2010;**12**(6):433-439
- [73] Soriano FX, Liesa M, Bach D, Chan DC, Palacin M, Zorzano A. Evidence for a mitochondrial regulatory pathway defined by peroxisome proliferator-activated receptor-gamma coactivator-1 alpha, estrogen-related receptor-alpha, and mitofusin 2. *Diabetes*. 2006;**55**(6):1783-1791
- [74] Roth GM, Sun B, Greensite FS, Lott IT, Dietrich RB. Premature aging in persons with Down syndrome: MR findings. *AJNR American Journal of Neuroradiology*. 1996;**17**(7):1283-1289
- [75] Nakamura E, Tanaka S. Biological ages of adult men and women with Down's syndrome and its changes with aging. *Mechanisms of Ageing and Development*. 1998;**105**(1-2):89-103
- [76] Angelopoulou N, Matziari C, Tsimaras V, Sakadamis A, Souftas V, Mandroukas K. Bone mineral density and muscle strength in young men with mental retardation (with and without Down syndrome). *Calcified Tissue International*. 2000;**66**(3):176-180
- [77] Thompson LV. Age-related muscle dysfunction. *Experimental Gerontology*. 2009;**44**(1-2):106-111
- [78] Busciglio J, Yankner BA. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. *Nature*. 1995;**378**(6559):776-779
- [79] Cenini G, Dowling AL, Beckett TL, Barone E, Mancuso C, Murphy MP, et al. Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome. *Biochimica et Biophysica Acta*. 2012;**1822**(2):130-138

- [80] Oettinghaus B, Schulz JM, Restelli LM, Licci M, Savoia C, Schmidt A, et al. Synaptic dysfunction, memory deficits and hippocampal atrophy due to ablation of mitochondrial fission in adult forebrain neurons. *Cell Death and Differentiation*. 2016;23(1):18-28
- [81] Emerit J, Edeas M, Bricaire F. Neurodegenerative diseases and oxidative stress. *Bio-medicine & Pharmacotherapy = Biomedecine & Pharmacotherapie*. 2004;58(1):39-46
- [82] Hroudova J, Singh N, Fisar Z. Mitochondrial dysfunctions in neurodegenerative diseases: Relevance to Alzheimer's disease. *BioMed Research International*. 2014;2014:175062
- [83] Zigman WB, Devenny DA, SJ K-MH, Jenkins EC, Urv TK, Wegiel J, et al. Alzheimer's disease in adults with down syndrome. *International Review of Research in Mental Retardation*. 2008;36:103-145
- [84] Head E, Silverman W, Patterson D, Lott IT. Aging and down syndrome. *Current Gerontology and Geriatrics Research*. 2012;2012:412536
- [85] Dumont M, Beal MF. Neuroprotective strategies involving ROS in Alzheimer disease. *Free Radical Biology & Medicine*. 2011;51(5):1014-1026
- [86] Misonou H, Morishima-Kawashima M, Ihara Y. Oxidative stress induces intracellular accumulation of amyloid beta-protein (Abeta) in human neuroblastoma cells. *Biochemistry*. 2000;39(23):6951-6959
- [87] Bertholet AM, Delerue T, Millet AM, Moulis MF, David C, Daloyau M, et al. Mitochondrial fusion/fission dynamics in neurodegeneration and neuronal plasticity. *Neurobiology of Disease*. 2016;90:3-19
- [88] Ferencz C, Neill CA, Boughman JA, Rubin JD, Brenner JL, Perry LW. Congenital cardiovascular malformations associated with chromosome abnormalities: An epidemiologic study. *The Journal of Pediatrics*. 1989;114(1):79-86
- [89] Park SC, Mathews RA, Zuberbuhler JR, Rowe RD, Neches WH, Lenox CC. Down syndrome with congenital heart malformation. *American Journal of Diseases of Children*. 1977;131(1):29-33
- [90] Bushdid PB, Osinska H, Waclaw RR, Molkentin JD, Yutzey KE. NFATc3 and NFATc4 are required for cardiac development and mitochondrial function. *Circulation Research*. 2003;92(12):1305-1313
- [91] de la Pompa JL, Timmerman LA, Takimoto H, Yoshida H, Elia AJ, Samper E, et al. Role of the NF-ATc transcription factor in morphogenesis of cardiac valves and septum. *Nature*. 1998;392(6672):182-186
- [92] Graef IA, Chen F, Crabtree GR. NFAT signaling in vertebrate development. *Current Opinion in Genetics & Development*. 2001;11(5):505-512
- [93] Wust RC, de Vries HJ, Wintjes LT, Rodenburg RJ, Niessen HW, Stienen GJ. Mitochondrial complex I dysfunction and altered NAD(P)H kinetics in rat myocardium in cardiac right ventricular hypertrophy and failure. *Cardiovascular Research*. 2016;111(4):362-372

- [94] Fritah A, Steel JH, Nichol D, Parker N, Williams S, Price A, et al. Elevated expression of the metabolic regulator receptor-interacting protein 140 results in cardiac hypertrophy and impaired cardiac function. *Cardiovascular Research*. 2010;**86**(3):443-451
- [95] Seok HY, Chen J, Kataoka M, Huang ZP, Ding J, Yan J, et al. Loss of MicroRNA-155 protects the heart from pathological cardiac hypertrophy. *Circulation Research*. 2014; **114**(10):1585-1595
- [96] Grammatikopoulou MG, Manai A, Tsigga M, Tsiligioglou-Fachantidou A, Galli-Tsinopoulou A, Zakas A. Nutrient intake and anthropometry in children and adolescents with Down syndrome—A preliminary study. *Developmental Neurorehabilitation*. 2008; **11**(4):260-267
- [97] Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. *Science*. 2005; **307**(5708):384-387
- [98] Ritov VB, Menshikova EV, He J, Ferrell RE, Goodpaster BH, Kelley DE. Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. *Diabetes*. 2005; **54**(1):8-14
- [99] Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. *Diabetes*. 2002; **51**(10):2944-2950
- [100] Hallberg M, Morganstein DL, Kiskinis E, Shah K, Kralli A, Dilworth SM, et al. A functional interaction between RIP140 and PGC-1alpha regulates the expression of the lipid droplet protein CIDEA. *Molecular Cell Biology*. 2008; **28**(22):6785-6795
- [101] Fritah A, Steel JH, Parker N, Nikolopoulou E, Christian M, Carling D, et al. Absence of RIP140 reveals a pathway regulating glut4-dependent glucose uptake in oxidative skeletal muscle through UCP1-mediated activation of AMPK. *PLoS One*. 2012; **7**(2):e32520
- [102] Leonardsson G, Steel JH, Christian M, Pocock V, Milligan S, Bell J, et al. Nuclear receptor corepressor RIP140 regulates fat accumulation. *Proceedings of the National Academy of Sciences of the United States of America*. 2004; **101**(22):8437-8442
- [103] Bach D, Pich S, Soriano FX, Vega N, Baumgartner B, Oriola J, et al. Mitofusin-2 determines mitochondrial network architecture and mitochondrial metabolism. A novel regulatory mechanism altered in obesity. *The Journal of Biological Chemistry*. 2003; **278**(19):17190-17197
- [104] Walder K, Kerr-Bayles L, Civitarese A, Jowett J, Curran J, Elliott K, et al. The mitochondrial rhomboid protease PSARL is a new candidate gene for type 2 diabetes. *Diabetologia*. 2005; **48**(3):459-468
- [105] Turner S, Sloper P, Cunningham C, Knussen C. Health problems in children with Down's syndrome. *Child: Care, Health and Development*. 1990; **16**(2):83-97
- [106] Selikowitz M. Health problems and health checks in school-aged children with Down syndrome. *Journal of Paediatrics and Child Health*. 1992; **28**(5):383-386

- [107] Cruz NV, Mahmoud SA, Chen H, Lowery-Nordberg M, Berlin K, Bahna SL. Follow-up study of immune defects in patients with dysmorphic disorders. *Annals of Allergy, Asthma & Immunology: Official Publication of the American College of Allergy, Asthma & Immunology.* 2009;**102**(5):426-431
- [108] van Trotsenburg AS, Kempers MJ, Endert E, Tijssen JG, de Vijlder JJ, Vulsmma T. Trisomy 21 causes persistent congenital hypothyroidism presumably of thyroidal origin. *Thyroid: Official Journal of the American Thyroid Association.* 2006;**16**(7):671-680
- [109] Zachor DA, Mroczeck-Musulman E, Brown P. Prevalence of celiac disease in Down syndrome in the United States. *Journal of Pediatric Gastroenterology and Nutrition.* 2000;**31**(3):275-279
- [110] Sanchez-Albisua I, Storm W, Wascher I, Stern M. How frequent is coeliac disease in Down syndrome? *European Journal of Pediatrics.* 2002;**161**(12):683-684
- [111] Kusters MA, Versteegen RH, Gemen EF, de Vries E. Intrinsic defect of the immune system in children with Down syndrome: A review. *Clinical and Experimental Immunology.* 2009;**156**(2):189-193
- [112] de Hingh YC, van der Vossen PW, Gemen EF, Mulder AB, Hop WC, Brus F, et al. Intrinsic abnormalities of lymphocyte counts in children with down syndrome. *The Journal of Pediatrics.* 2005;**147**(6):744-747
- [113] Aburawi EH, Soid AK. Lymphocyte respiration in children with Trisomy 21. *BMC Pediatrics.* 2012;**12**:193
- [114] Campello S, Lacalle RA, Bettella M, Manes S, Scorrano L, Viola A. Orchestration of lymphocyte chemotaxis by mitochondrial dynamics. *The Journal of Experimental Medicine.* 2006;**203**(13):2879-2886
- [115] Buck MD, O'Sullivan D, Klein Geltink RI, Curtis JD, Chang CH, Sanin DE, et al. Mitochondrial dynamics controls T cell fate through metabolic programming. *Cell.* 2016;**166**(1):63-76
- [116] de la Torre R, Dierssen M. Therapeutic approaches in the improvement of cognitive performance in Down syndrome: past, present, and future. *Progress in Brain Research.* 2012;**197**:1-14
- [117] Costa AC, Scott-McKean JJ. Prospects for improving brain function in individuals with Down syndrome. *CNS Drugs.* 2013;**27**(9):679-702
- [118] Gardiner KJ. Pharmacological approaches to improving cognitive function in Down syndrome: Current status and considerations. *Drug Design, Development and Therapy.* 2015;**9**:103-125
- [119] Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. *Nature.* 2005;**434**(7029):113-118

- [120] Dong W, Gao D, Zhang X. Mitochondria biogenesis induced by resveratrol against brain ischemic stroke. *Medical Hypotheses*. 2007;69(3):700-701
- [121] Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. *Cell*. 2006;127(6):1109-1122
- [122] Jager S, Handschin C, St-Pierre J, Spiegelman BM. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. *Proceedings of the National Academy of Sciences of the United States of America*. 2007;104(29):12017-12022
- [123] Nicolakakis N, Aboulkassim T, Ongali B, Lecrux C, Fernandes P, Rosa-Neto P, et al. Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience*. 2008;28(37):9287-9296
- [124] Escribano L, Simon AM, Perez-Mediavilla A, Salazar-Colcho P, Del Rio J, Frechilla D. Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model. *Biochemical and Biophysical Research Communications*. 2009;379(2):406-410
- [125] Johri A, Calingasan NY, Hennessey TM, Sharma A, Yang L, Wille E, et al. Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease. *Human Molecular Genetics*. 2012;21(5):1124-1137
- [126] Yamaguchi S, Li H, Purevsuren J, Yamada K, Furui M, Takahashi T, et al. Bezafibrate can be a new treatment option for mitochondrial fatty acid oxidation disorders: Evaluation by in vitro probe acylcarnitine assay. *Molecular Genetics and Metabolism*. 2012;107(1-2):87-91
- [127] Canto C, Auwerx J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. *Current Opinion in Lipidology*. 2009;20(2):98-105
- [128] Hofer A, Noe N, Tischner C, Kladt N, Lellek V, Schauss A, et al. Defining the action spectrum of potential PGC-1alpha activators on a mitochondrial and cellular level in vivo. *Human Molecular Genetics*. 2014;23(9):2400-2415
- [129] Lott IT, Doran E, Nguyen VQ, Tournay A, Head E, Gillen DL. Down syndrome and dementia: A randomized, controlled trial of antioxidant supplementation. *American Journal of Medical Genetics. Part A*. 2011;155A(8):1939-1948
- [130] Miles MV, Patterson BJ, Chalfonte-Evans ML, Horn PS, Hickey FJ, Schapiro MB, et al. Coenzyme Q10 (ubiquinol-10) supplementation improves oxidative imbalance in children with trisomy 21. *Pediatric Neurology*. 2007;37(6):398-403
- [131] Ellis JM, Tan HK, Gilbert RE, Muller DP, Henley W, Moy R, et al. Supplementation with antioxidants and folic acid for children with Down's syndrome: Randomised controlled trial. *BMJ*. 2008;336(7644):594-597

- [132] Reynolds T. Antioxidants do not improve early childhood development in children with Down's syndrome. *The Journal of Pediatrics*. 2008;153(3):441
- [133] Sano M, Aisen PS, Andrews HF, Tsai WY, Lai F, Dalton AJ, et al. Vitamin E in aging persons with Down syndrome: A randomized, placebo-controlled clinical trial. *Neurology*. 2016;86(22):2071-2076
- [134] Littarru GP, Tiano L. Clinical aspects of coenzyme Q10: An update. *Nutrition*. 2010; 26(3):250-254
- [135] Uberos J, Romero J, Molina-Carballo A, Munoz-Hoyos A. Melatonin and elimination of kynurenes in children with Down's syndrome. *Journal of Pediatric Endocrinology & Metabolism: JPEM*. 2010;23(3):277-282
- [136] Parisotto EB, Vidal V, Garcia-Cerro S, Lantigua S, Wilhelm Filho D, Sanchez-Barcelo EJ, et al. Chronic melatonin administration reduced oxidative damage and cellular senescence in the hippocampus of a mouse model of down syndrome. *Neurochemical Research*. 2016;41(11):2904-2913
- [137] Corrales A, Parisotto EB, Vidal V, Garcia-Cerro S, Lantigua S, Diego M, et al. Pre- and post-natal melatonin administration partially regulates brain oxidative stress but does not improve cognitive or histological alterations in the Ts65Dn mouse model of Down syndrome. *Behavioural Brain Research*. 2017;334:142-154
- [138] Schroeder EK, Kelsey NA, Doyle J, Breed E, Bouchard RJ, Loucks FA, et al. Green tea epigallocatechin 3-gallate accumulates in mitochondria and displays a selective antiapoptotic effect against inducers of mitochondrial oxidative stress in neurons. *Antioxidants & Redox Signaling*. 2009;11(3):469-480
- [139] Srividhya R, Zarkovic K, Stroser M, Waeg G, Zarkovic N, Kalaiselvi P. Mitochondrial alterations in aging rat brain: Effective role of (-)-epigallo catechin gallate. *International Journal of Developmental Neuroscience: The Official Journal of the International Society for Developmental Neuroscience*. 2009;27(3):223-231
- [140] Rezai-Zadeh K, Shytle D, Sun N, Mori T, Hou H, Jeanniton D, et al. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience*. 2005;25(38):8807-8814
- [141] Dragicevic N, Smith A, Lin X, Yuan F, Copes N, Delic V, et al. Green tea epigallocatechin-3-gallate (EGCG) and other flavonoids reduce Alzheimer's amyloid-induced mitochondrial dysfunction. *Journal of Alzheimer's Disease: JAD*. 2011;26(3):507-521
- [142] Feng Y, Wu J, Chen L, Luo C, Shen X, Chen K, et al. A fluorometric assay of SIRT1 deacetylation activity through quantification of nicotinamide adenine dinucleotide. *Analytical Biochemistry*. 2009;395(2):205-210

- [143] Alvarez E, Campos-Toimil M, Justiniano-Basaran H, Lugnier C, Orallo F. Study of the mechanisms involved in the vasorelaxation induced by (-)-epigallocatechin-3-gallate in rat aorta. *British Journal of Pharmacology*. 2006;147(3):269-280
- [144] Ok WJ, Cho HJ, Kim HH, Lee DH, Kang HY, Kwon HW, et al. Epigallocatechin-3-gallate has an anti-platelet effect in a cyclic AMP-dependent manner. *Journal of Atherosclerosis and Thrombosis*. 2012;19(4):337-348
- [145] Guedj F, Sebrie C, Rivals I, Ledru A, Paly E, Bizot JC, et al. Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A. *PLoS One*. 2009;4(2):e4606
- [146] Valenti D, De Rasmo D, Signorile A, Rossi L, de Bari L, Scala I, et al. Epigallocatechin-3-gallate prevents oxidative phosphorylation deficit and promotes mitochondrial biogenesis in human cells from subjects with Down's syndrome. *Biochimica et Biophysica Acta*. 2013;1832(4):542-552
- [147] De la Torre R, De Sola S, Pons M, Duchon A, de Lagran MM, Farre M, et al. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans. *Molecular Nutrition & Food Research*. 2014;58(2):278-288
- [148] Stagni F, Giacomini A, Emili M, Trazzi S, Guidi S, Sassi M, et al. Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome. *Neuroscience*. 2016;333:277-301
- [149] McElyea SD, Starbuck JM, Tumbleston-Brink DM, Harrington E, Blazek JD, Ghoneima A, et al. Influence of prenatal EGCG treatment and Dyrk1a dosage reduction on craniofacial features associated with Down syndrome. *Human Molecular Genetics*. 2016;25(22):4856-4869
- [150] Stringer M, Abeysekera I, Thomas J, LaCombe J, Stancombe K, Stewart RJ, et al. Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes. *Physiology & Behavior*. 2017;177:230-241
- [151] Qanungo S, Das M, Haldar S, Basu A. Epigallocatechin-3-gallate induces mitochondrial membrane depolarization and caspase-dependent apoptosis in pancreatic cancer cells. *Carcinogenesis*. 2005;26(5):958-967
- [152] Kim HS, Quon MJ, Kim JA. New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate. *Redox Biology*. 2014;2:187-195
- [153] Porquet D, Casadesus G, Bayod S, Vicente A, Canudas AM, Vilaplana J, et al. Dietary resveratrol prevents Alzheimer's markers and increases life span in SAMP8. *Age*. 2013;35(5):1851-1865

- [154] Alagiakrishnan K, Sankaralingam S, Ghosh M, Mereu L, Senior P. Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer's disease. *Discovery Medicine*. 2013;**16**(90):277-286
- [155] Caton PW, Nayuni NK, Kieswich J, Khan NQ, Yaqoob MM, Corder R. Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. *The Journal of Endocrinology*. 2010;**205**(1):97-106
- [156] Wang J, Gallagher D, DeVito LM, Cancino GI, Tsui D, He L, et al. Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation. *Cell Stem Cell*. 2012;**11**(1):23-35
- [157] Salomaki H, Vahatalo LH, Laurila K, Jappinen NT, Penttinen AM, Ailanen L, et al. Prenatal metformin exposure in mice programs the metabolic phenotype of the offspring during a high fat diet at adulthood. *PLoS One*. 2013;**8**(2):e56594
- [158] Labuzek K, Suchy D, Gabryel B, Bielecka A, Liber S, Okopien B. Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. *Pharmacological Reports: PR*. 2010;**62**(5):956-965